Phase III programme of GSK 573719 plus vilanterol (Glaxo Smith Kline/Theravance) for COPD completed

The Phase III programme of GSK 573719 plus vilanterol, from Glaxo Smith Kline and Theravance, involving approximately 6,000 patients with Chronic Obstructive Pulmonary Disease (COPD) has been completed. On 2 July 2012, GSK and Theravance announced the completion of four pivotal studies for GSK 573719 plus vilanterol. The pivotal programme for the drug combo also includes a 52-week safety study, which is now complete. Two non-pivotal 12-week crossover exercise studies will also be included in the registrational package as they are now also complete. These recently completed studies support GSK�s plans to commence global regulatory submissions for GSK 573719 plus vilanterol from the end of 2012. The full results of all these studies, together with additional data from phase IIb dose-ranging studies of UMEC, will be presented at future scientific meetings.